Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Harbour BioMed
Biotech
Harbour ships phase 3 data to take lead in autoimmune race
Harbour is the first company to show an anti-FcRn drug improves generalized myasthenia gravis in China, putting it ahead of rivals such as J&J.
Nick Paul Taylor
Mar 6, 2023 6:50am
Cullinan plucks US rights to Harbour BioMed's novel bispecific
Feb 13, 2023 7:00pm
Moderna's appetite for antibody tech spurs $6M biotech bet
Nov 11, 2022 7:30am
AstraZeneca bets $25M on pre-clinic bispecific versus hot target
Apr 7, 2022 7:00am
Harbour BioMed nabs meaty C round
Jul 10, 2020 7:40am
After Kaletra setback, AbbVie joins forces for COVID hopeful pe
Jun 5, 2020 8:50am